These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 25418443

  • 1. No excess risks in offspring with paternal preconception exposure to disease-modifying antirheumatic drugs.
    Wallenius M, Lie E, Daltveit AK, Salvesen KÅ, Skomsvoll JF, Kalstad S, Lexberg ÅS, Mikkelsen K, Kvien TK, Østensen M.
    Arthritis Rheumatol; 2015 Jan; 67(1):296-301. PubMed ID: 25418443
    [Abstract] [Full Text] [Related]

  • 2. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers.
    Viktil KK, Engeland A, Furu K.
    Scand J Rheumatol; 2012 May; 41(3):196-201. PubMed ID: 22401133
    [Abstract] [Full Text] [Related]

  • 3. Investigating paternal preconception risk factors for adverse pregnancy outcomes in a population of internet users.
    Agricola E, Gesualdo F, Carloni E, D'Ambrosio A, Russo L, Campagna I, Pandolfi E, Tozzi AE.
    Reprod Health; 2016 Apr 14; 13():37. PubMed ID: 27080860
    [Abstract] [Full Text] [Related]

  • 4. Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence.
    Mouyis M, Flint JD, Giles IP.
    Semin Arthritis Rheum; 2019 Apr 14; 48(5):911-920. PubMed ID: 30220537
    [Abstract] [Full Text] [Related]

  • 5. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study.
    Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Network of French Pharmacovigilance Centers, Shechtman S, Johnson D, Cuppers-Maarschalkerweerd B, Pistelli A, Clementi M, Winterfeld U, Eleftheriou G, Pupco A, Kao K, Malm H, Elefant E, Koren G, Vial T, Ornoy A, Meister R, Schaefer C.
    Arthritis Rheumatol; 2014 May 14; 66(5):1101-10. PubMed ID: 24470106
    [Abstract] [Full Text] [Related]

  • 6. Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis-results from a JIA biologic registry.
    Drechsel P, Stüdemann K, Niewerth M, Horneff G, Fischer-Betz R, Seipelt E, Spähtling-Mestekemper S, Aries P, Zink A, Klotsche J, Minden K.
    Rheumatology (Oxford); 2020 Mar 01; 59(3):603-612. PubMed ID: 31412128
    [Abstract] [Full Text] [Related]

  • 7. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM.
    Dan Med Bull; 2011 Dec 01; 58(12):B4360. PubMed ID: 22142578
    [Abstract] [Full Text] [Related]

  • 8. Paternal safety of anti-rheumatic medications.
    Bermas BL.
    Best Pract Res Clin Obstet Gynaecol; 2020 Apr 01; 64():77-84. PubMed ID: 31727565
    [Abstract] [Full Text] [Related]

  • 9. Use of antirheumatic drugs in mothers and fathers before and during pregnancy-a population-based cohort study.
    Viktil KK, Engeland A, Furu K.
    Pharmacoepidemiol Drug Saf; 2009 Aug 01; 18(8):737-42. PubMed ID: 19504626
    [Abstract] [Full Text] [Related]

  • 10. Safety of biologic immunosuppressants in pregnant women with immune-mediated inflammatory diseases.
    N MS, Álvarez-Troncoso J, Robles-Marhuenda Á, De la Calle Fernández-Miranda M, Muner Hernando ML, Bartha JL.
    J Autoimmun; 2024 Sep 01; 148():103301. PubMed ID: 39141986
    [Abstract] [Full Text] [Related]

  • 11. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study.
    Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, Meister R, Schaefer C.
    Rheumatology (Oxford); 2014 Apr 01; 53(4):757-63. PubMed ID: 24369411
    [Abstract] [Full Text] [Related]

  • 12. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C, Kvien TK, Mikkelsen K, Kaufmann C, Rødevand E, Nossent JC.
    Scand J Rheumatol; 2009 Apr 01; 38(4):240-5. PubMed ID: 19229766
    [Abstract] [Full Text] [Related]

  • 13. Biologic therapy use and pregnancy outcomes in women with immune-mediated inflammatory rheumatic diseases.
    Brites L, Madeira N, Rodrigues J, Marona J, Martins N, Águeda A, Freitas R, Neto A, Capela S, Sequeira G, Ganhão S, Duarte C, Santiago M, Santos MJ.
    Acta Reumatol Port; 2019 Apr 01; 44(4):266-272. PubMed ID: 32008032
    [Abstract] [Full Text] [Related]

  • 14. Patterns of medication use during pregnancy in rheumatoid arthritis.
    Kuriya B, Hernández-Díaz S, Liu J, Bermas BL, Daniel G, Solomon DH.
    Arthritis Care Res (Hoboken); 2011 May 01; 63(5):721-8. PubMed ID: 21557526
    [Abstract] [Full Text] [Related]

  • 15. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes.
    Chakravarty EF, Sanchez-Yamamoto D, Bush TM.
    J Rheumatol; 2003 Feb 01; 30(2):241-6. PubMed ID: 12563675
    [Abstract] [Full Text] [Related]

  • 16. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.
    Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N, Dolhain R, Förger F, Khamashta M, Ruiz-Irastorza G, Zink A, Vencovsky J, Cutolo M, Caeyers N, Zumbühl C, Østensen M.
    Ann Rheum Dis; 2016 May 01; 75(5):795-810. PubMed ID: 26888948
    [Abstract] [Full Text] [Related]

  • 17. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN, van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, Brouwers JR.
    Clin Ther; 2009 Aug 01; 31(8):1737-46. PubMed ID: 19808132
    [Abstract] [Full Text] [Related]

  • 18. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases.
    Meserve J, Luo J, Zhu W, Veeravalli N, Bandoli G, Chambers CD, Singh AG, Boland BS, Sandborn WJ, Mahadevan U, Singh S.
    Gastroenterology; 2021 Jul 01; 161(1):107-115.e3. PubMed ID: 33744307
    [Abstract] [Full Text] [Related]

  • 19. Disease-modifying anti-rheumatic drug use in pregnant women with rheumatic diseases: a systematic review of the risk of congenital malformations.
    Baldwin C, Avina-Zubieta A, Rai SK, Carruthers E, De Vera MA.
    Clin Exp Rheumatol; 2016 Jul 01; 34(2):172-83. PubMed ID: 26940667
    [Abstract] [Full Text] [Related]

  • 20. Prescribing of sulfasalazine, azathioprine and methotrexate round pregnancy--a descriptive study.
    Vroom F, van Roon EN, van den Berg PB, Brouwers JR, de Jong-van den Berg LT.
    Pharmacoepidemiol Drug Saf; 2008 Jan 01; 17(1):52-61. PubMed ID: 17948319
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.